Literature DB >> 8132318

Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

G B Pier1, N L Koles, G Meluleni, K Hatano, M Pollack.   

Abstract

Structural and antigenic heterogeneity has been noted among lipopolysaccharides (LPS) produced by Pseudomonas aeruginosa within serogroups previously considered to be serologically homogeneous. We characterized murine monoclonal antibodies (MAbs) and immunization-induced human polyclonal antibodies reactive with one or more of five structurally variant LPS subtypes belonging to serogroup 06 of the International Antigenic Typing System. Analyses of five different MAbs employing purified LPS or whole patterns of subtype specificity, ranging from recognition of a single subtype to reactivity with all five. MAb-mediated opsonophagocytic killing and in vivo protection against live challenge in mice correlated, in general, with differential binding to various LPS subtypes. In comparison, sera from human vaccinees immunized with LPS-derived high-molecular-weight polysaccharide from P. aeruginosa Fisher immunotype 1, one of five serogroup 06 subtypes, exhibited LPS binding and opsonic activity against all five subtypes. Antibodies in the human sera effectively inhibited binding to all five LPS subtype antigens of the cross-reactive MAb, LC3-2H2, suggesting the existence of a common serogroup-related epitope. These findings emphasize the importance of defining subtype-associated variations in LPS antigenicity and corresponding differences in antibody specificity and function as a basis for designing immunoprophylactic or therapeutic strategies which target P. aeruginosa LPS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132318      PMCID: PMC186240          DOI: 10.1128/iai.62.4.1137-1143.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

Authors:  M Pollack; J K Chia; N L Koles; M Miller; G Guelde
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

Review 3.  Conjugate vaccines against Pseudomonas aeruginosa and malaria.

Authors:  S J Cryz; J C Sadoff; J U Que
Journal:  Contrib Microbiol Immunol       Date:  1989

4.  Three new major somatic antigens of Pseudomonas aeruginosa.

Authors:  P V Liu; S Wang
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 5.  Pseudomonas aeruginosa. Vaccines and immunotherapy.

Authors:  J E Pennington
Journal:  Infect Dis Clin North Am       Date:  1990-06       Impact factor: 5.982

6.  Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Microb Pathog       Date:  1989-01       Impact factor: 3.738

Review 7.  Polysaccharide antigens of Pseudomonas aeruginosa.

Authors:  Y A Knirel
Journal:  Crit Rev Microbiol       Date:  1990       Impact factor: 7.624

8.  Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.

Authors:  S J Cryz; E Fürer; J C Sadoff; T Fredeking; J U Que; A S Cross
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Molecular cloning of genes involved with expression of A-band lipopolysaccharide, an antigenically conserved form, in Pseudomonas aeruginosa.

Authors:  J Lightfoot; J S Lam
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

10.  Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.

Authors:  S J Cryz; E Fürer; J U Que
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.609

View more
  6 in total

1.  Naturally acquired antibodies against four Enterococcus faecalis capsular polysaccharides in healthy human sera.

Authors:  Markus Hufnagel; Andrea Kropec; Christian Theilacker; Johannes Huebner
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies.

Authors:  G B Pier; G Meluleni; J B Goldberg
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

3.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

4.  Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).

Authors:  K Hatano; J B Goldberg; G B Pier
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

5.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

6.  Assessment of Pasteurella multocida A Lipopolysaccharide, as an Adhesin in an In Vitro Model of Rabbit Respiratory Epithelium.

Authors:  Carolina Gallego; Stefany Romero; Paula Esquinas; Pilar Patiño; Nhora Martínez; Carlos Iregui
Journal:  Vet Med Int       Date:  2017-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.